Radiation plus engineered NK cells for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck cancer that has spread or come back, and standard treatments are no longer working or are not available.
- Your tumor must test positive for a marker called TROP2 (a score of 2+ or 3+ on a special test).
- You will need to have radiation to at least one tumor site, and if you have multiple tumors, at least one will not be radiated.
- You must be 18 or older, be able to care for yourself (ECOG 0 or 1), and have adequate organ function (kidney, liver, blood counts, heart and lungs).
- Women who can have children and men must agree to use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
This early-phase study tests a lab-made treatment using your own immune cells (T cells) to target HPV-related throat cancers. It aims to reduce cancer by directing your immune system against HPV16/HPV18 and a protein called survivin.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.